Approval · Notice of Compliance 12569 · 2011
EDURANT: Notice of Compliance 12569
Issued July 21, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12569
- Date
- July 21, 2011
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Human Immunodeficiency Virus (HIV) Non-nNucleoside Reverse Transcriptasee Inhibitor
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EDURANT | 02370603 | Marketed |
Medicinal ingredients
- RILPIVIRINE HYDROCHLORIDE 25 MG per TAB